Litcius/Paper detail

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Alison R. Sehgal, Daanish Hoda, Peter A. Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard Hildebrandt, John E. Godwin, Patrick M. Reagan, Nina D. Wagner‐Johnston, James Essell, Rajneesh Nath, Scott R. Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel K. Gupta, Ronald L. Dubowy, Aleco D’Andrea, Lei Wang, K. OGASAWARA, Jerill Thorpe, Leo I. Gordon

2022The Lancet Oncology235 citationsDOI

Topics & Concepts

Refractory (planetary science)LymphomaTransplantationMedicineStem cellHaematopoiesisHematopoietic cellOncologyInternal medicineBiologyGeneticsAstrobiologyCAR-T cell therapy researchLymphoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers